Watch IBRX. Know when insiders buy.
One email the day a filing lands. Free.
IBRX
ImmunityBio, Inc.
8.46
+0.55 +6.95%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $9BP/E —DIV YIELD —FCF YIELD -3.21%REV TTM $165.8M +192.9%NET INCOME −$992.4MNET CASH $74.8M52W 1.98 – 11.55SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $51.2M | +93.9% | 99.4% | −$61.7M | −$230.4M | — | -0.22 | −$66.5M | $3.5M | −$70M | Aug 4 |
| Q1 2026 · Mar 31 | $44.2M | +167.6% | 99.5% | −$69.8M | −$632.8M | — | -0.62 | −$75.4M | $1.8M | −$77.1M | May 7 |
| Q4 2025 · Dec 31derived | $38.3M | +407.0% | 99.0% | −$64.7M | −$61.9M | — | -0.06 | −$70.4M | $903K | −$71.3M | Feb 23 |
| Q3 2025 · Sep 30 | $32.1M | +425.1% | 99.4% | −$55.6M | −$67.3M | — | -0.07 | −$68.9M | $741K | −$69.6M | Nov 5 |
| Q2 2025 · Jun 30 | $26.4M | +2423.9% | 99.5% | −$71.3M | −$92.6M | — | -0.10 | −$79.7M | $1.1M | −$80.8M | Aug 4 |
| Q1 2025 · Mar 31 | $16.5M | +41192.5% | 99.6% | −$64.4M | −$129.6M | — | -0.15 | −$85.9M | $1.1M | −$87M | May 7 |
| Q4 2024 · Dec 31derived | $7.6M | +5333.1% | 100.0% | −$69.4M | −$59.2M | — | -0.09 | −$85.1M | $2.1M | −$87.3M | Feb 23 |
| Q3 2024 · Sep 30 | $6.1M | +7346.3% | 100.0% | −$80.3M | −$85.7M | — | -0.14 | −$98.8M | $2.8M | −$101.6M | Nov 5 |
| Q2 2024 · Jun 30 | $1M | — | 100.0% | −$99.3M | −$134.6M | — | -0.20 | −$100.3M | $724K | −$101.1M | Aug 5 |
| Q1 2024 · Mar 31 | $40K | — | 100.0% | −$95.2M | −$134.1M | — | -0.20 | −$107M | $1.3M | −$108.2M | May 12 |
| Q4 2023 · Dec 31derived | $139K | — | 100.0% | −$85.4M | −$233.4M | — | -0.38 | −$115.3M | $8M | −$123.2M | Feb 23 |
| Q3 2023 · Sep 30 | $82K | — | 100.0% | −$80.1M | −$95.6M | — | -0.19 | −$87.4M | $5.7M | −$93.1M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $113.3M | 99.3% | −$256M | −$351.4M | -310.2% | -0.38 | −$304.9M | $3.8M | −$308.8M | — | — |
| FY2024 · to Dec 31 | $14.7M | 100.0% | −$344.2M | −$413.6M | -2804.8% | -0.62 | −$391.2M | $6.9M | −$398.1M | — | — |
| FY2023 · to Dec 31 | $622K | 100.0% | −$362.3M | −$583.2M | -93761.4% | -1.15 | −$366.8M | $30.6M | −$397.3M | — | — |
| FY2022 · to Dec 31 | $240K | 100.0% | −$351.3M | −$416.6M | -173569.6% | -1.04 | −$337.5M | $78.2M | −$415.7M | — | — |
| FY2021 · to Dec 31 | $934K | — | −$330.3M | −$346.8M | -37129.6% | -0.89 | −$274.4M | $33.6M | −$308M | $0 | — |
| FY2020 · to Dec 31 | $605K | — | −$220.9M | −$221.9M | -36669.6% | -0.59 | −$171.7M | $1.7M | −$173.4M | $0 | — |
Every number comes from ImmunityBio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.